NASDAQ:HSKA - Heska Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heska Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $56.53 +3.12 (+5.84 %) (As of 03/30/2020 04:00 PM ET) Add Compare Today's Range$50.31Now: $56.53▼$57.0050-Day Range$52.76MA: $87.91▼$103.2352-Week Range$50.00Now: $56.53▼$110.90Volume138,435 shsAverage Volume79,615 shsMarket Capitalization$443.08 millionP/E RatioN/ADividend YieldN/ABeta1.12 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSKA Previous Symbol CUSIPN/A CIK1038133 Webhttp://www.heska.com/ Phone970-493-7272Debt Debt-to-Equity Ratio0.32 Current Ratio4.34 Quick Ratio3.52Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$122.66 million Price / Sales3.61 Cash Flow$0.97 per share Price / Cash Flow58.44 Book Value$19.72 per share Price / Book2.87Profitability EPS (Most Recent Fiscal Year)$0.05 Net Income$-1,470,000.00 Net Margins-1.07% Return on Equity0.08% Return on Assets0.06%Miscellaneous Employees347 Outstanding Shares7,838,000Market Cap$443.08 million Next Earnings Date5/5/2020 (Estimated) OptionableNot Optionable Receive HSKA News and Ratings via Email Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HSKA Rates by TradingView Heska (NASDAQ:HSKA) Frequently Asked Questions How has Heska's stock been impacted by COVID-19 (Coronavirus)? Heska's stock was trading at $81.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HSKA stock has decreased by 30.9% and is now trading at $56.53. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Heska? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Heska. When is Heska's next earnings date? Heska is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Heska. How were Heska's earnings last quarter? Heska Corp (NASDAQ:HSKA) issued its quarterly earnings data on Tuesday, February, 25th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.21. The medical research company earned $33.77 million during the quarter, compared to analyst estimates of $34.29 million. Heska had a negative net margin of 1.07% and a positive return on equity of 0.08%. View Heska's earnings history. What guidance has Heska issued on next quarter's earnings? Heska issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-145 million, compared to the consensus revenue estimate of $141.76 million. What price target have analysts set for HSKA? 6 brokerages have issued 12 month target prices for Heska's stock. Their forecasts range from $59.00 to $107.00. On average, they expect Heska's stock price to reach $84.75 in the next year. This suggests a possible upside of 49.9% from the stock's current price. View analysts' price targets for Heska. What are Wall Street analysts saying about Heska stock? Here are some recent quotes from research analysts about Heska stock: 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (2/27/2020) 2. Canaccord Genuity analysts commented, "We view this financing as overdue" as the company had been operating for some time at a cash balance hovering around $10 million. We trim our out year revenue and earnings estimates as we exercise more conservatism on Heska’s top line growth, and we expect a higher level of spending to help return the company to growth, following ~3 years of missing expectations. We are cautiously optimistic to see Heska deliver on its growth initiatives, however, our near-term expectations are tempered until we see evidence of stronger commercial execution. While we trim our estimates and price target to $75 (from $95), we are sticking with our BUY rating in hopes we see progress on new product and geographic expansion as we look out to 2020. Convertible notes." (9/12/2019) Has Heska been receiving favorable news coverage? Media stories about HSKA stock have been trending negative on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Heska earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutHeska. Are investors shorting Heska? Heska saw a increase in short interest in February. As of February 28th, there was short interest totaling 866,600 shares, an increase of 5.1% from the February 13th total of 824,900 shares. Based on an average daily volume of 67,300 shares, the days-to-cover ratio is currently 12.9 days. Currently, 12.7% of the company's stock are short sold. View Heska's Current Options Chain. Who are some of Heska's key competitors? Some companies that are related to Heska include Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Lantheus (LNTH), Meridian Bioscience (VIVO), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), GeneNews (GNWSF), Achieve Life Sciences (ACHV) and Arca Biopharma (ABIO). What other stocks do shareholders of Heska own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Broadcom (AVGO), Netflix (NFLX), Biogen (BIIB), Western Digital (WDC), Exxon Mobil (XOM), Exelixis (EXEL), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA) and Walt Disney (DIS). Who are Heska's key executives? Heska's management team includes the following people: Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)Mr. Jason A. Napolitano, COO & Chief Strategist (Age 51)Ms. Catherine I. Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 56)Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 44) What is Heska's stock symbol? Heska trades on the NASDAQ under the ticker symbol "HSKA." Who are Heska's major shareholders? Heska's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Fred Alger Management LLC (13.32%), Standard Life Aberdeen plc (3.78%), Riverbridge Partners LLC (3.70%), State Street Corp (3.63%), FMR LLC (3.05%) and SG Capital Management LLC (2.33%). Company insiders that own Heska stock include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Nancy Wisnewski, Rod Lippincott, Scott Humphrey, Steve Asakowicz and Steven M Eyl. View institutional ownership trends for Heska. Which institutional investors are selling Heska stock? HSKA stock was sold by a variety of institutional investors in the last quarter, including SG Capital Management LLC, Standard Life Aberdeen plc, SG Americas Securities LLC, State Street Corp, Grace & White Inc. NY, Jane Street Group LLC, Citigroup Inc., and US Bancorp DE. View insider buying and selling activity for Heska. Which institutional investors are buying Heska stock? HSKA stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Public Sector Pension Investment Board, Aviva PLC, Russell Investments Group Ltd., Geode Capital Management LLC, Great West Life Assurance Co. Can, Nuveen Asset Management LLC, and Fred Alger Management LLC. View insider buying and selling activity for Heska. How do I buy shares of Heska? Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Heska's stock price today? One share of HSKA stock can currently be purchased for approximately $56.53. How big of a company is Heska? Heska has a market capitalization of $443.08 million and generates $122.66 million in revenue each year. The medical research company earns $-1,470,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Heska employs 347 workers across the globe. View additional information about Heska. What is Heska's official website? The official website for Heska is http://www.heska.com/. How can I contact Heska? Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected] MarketBeat Community Rating for Heska (NASDAQ HSKA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 315 (Vote Outperform)Underperform Votes: 352 (Vote Underperform)Total Votes: 667MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/30/2020 by MarketBeat.com StaffFeatured Article: What is the Russell 2000 Index?
